StreetInsider.com News Articles

iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch

Wed, 14 Oct 2026 08:00:00 -0400

NASHVILLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced the appointment of Donnie Purto as Senior Vice President of Sales to lead the company’s commercialization efforts as it prepares to bring GraftAssureDx to market. GraftAssureDx is currently under FDA medical device review and is awaiting regulatory authorization.

Mr. Purto is an accomplished sales leader with more than 20 years of experience building and leading high-performing sales organizations across diagnostics, life sciences and healthcare. During a decade at Natera, Inc., he had success in leadership roles spanning sales, training, oncology, transplant

iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch

Wed, 14 Oct 2026 08:00:00 -0400

iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings

Mon, 12 Oct 2026 08:00:00 -0400

NASHVILLE, Tenn., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that on October 14, 2026, it will participate in the U.S. Bancorp I BTIG Kidney Health Forum, which will include a key opinion leader (KOL) virtual discussion and one-on-one meetings between investors and management.

The KOL discussion will feature iMDx CEO Josh Riggs, as well as Prof. Dr. Med. Klemens Budde, who is a kidney transplantation researcher and a head of the transplant program of the Department of Nephrology and Internal Intensive Care Medicine, at the Charité – Universitätsmedizin Berlin. Charité

iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings

Mon, 12 Oct 2026 08:00:00 -0400

Form 8-K Insight Molecular Diagno For: Sep 15

Mon, 21 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260921/27085380.html

Lucid Capital Markets Starts Insight Molecular Diagnostics Inc. (IMDX) at Buy

Mon, 24 Aug 2026 06:09:11 -0400

Lucid Capital Markets analyst Alex Nowak initiates coverage on Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) with a Buy rating and a price target of $8.00.

The analyst comments "Decentralized Kitted Model: IMDX is seeking to compete directly against the send-out central lab model. Instead of shipping samples for complex lab tests across the U.S., IMDX hands a local hospital lab a kit to run a similar test in-house on a Bio-Rad Droplet Digital PCR instrument. The payoff is four-fold: same-day or next-day results, the hospital retains the reimbursement economics, the test slots into the laboratory workflows that hospital labs already run,

Lucid Capital Markets Starts Insight Molecular Diagnostics Inc. (IMDX) at Buy

Mon, 24 Aug 2026 06:09:11 -0400

Lucid Capital Markets analyst Alex Nowak initiates coverage on Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) with a Buy rating and a price target of $8.00.

Needham: 'we think that the event was positive for IMDX'

Tue, 18 Aug 2026 08:35:44 -0400

Needham: 'we think that the event was positive for IMDX'.

The analyst comments "Yesterday, IMDX hosted a webinar with Max Jacob Liebo, MD from the Loyola University Medical Center. Dr. Liebo is a cardiologist at Loyola University Medical Center, focused on comprehensive heart and vascular care, and cares for a number of heart transplant patients. He was very positive on donor-derived cell free DNA (dd-cfDNA) testing, noting that he uses the assays in 100% of his patients and believes that over time, as clinical evidence builds, dd-cfDNA will be the primary method for both surveillance and for-cause rejection testing. He currently

Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing

Tue, 11 Aug 2026 16:05:00 -0400

NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo, MD (Loyola University Medical Center), who will join Nick Ioannou, MD, MHA (iMDx VP Medical Affairs) and Josh Riggs (iMDx CEO), to discuss the Company's GraftAssure platform, which leverages digital PCR technology to deliver reliable dd-cfDNA results for transplanted organ health monitoring. To register, click here.